Table 1.
Characteristics of the study population (mortality data observed from death certificates, France, 2000–2013)
| Gender | Cause of death | Number (%) | Age at death, median [IQR] | |
|---|---|---|---|---|
| Men | Overall | 3,685,024 (100) | 76 [64–84] | |
| Suicide | Bladder cancer | 150 (0) | 78 [69–83] | |
| CNS cancer | 20 (0) | 56 [45–64] | ||
| Colorectal cancer | 331 (0) | 75 [68–81] | ||
| Cutaneous melanoma | 13 (0) | 76 [58–80] | ||
| Head and neck cancer | 157 (0) | 65 [55–75] | ||
| Kidney cancer | 77 (0) | 71 [65–77] | ||
| Larynx cancer | 103 (0) | 67 [57–75] | ||
| Liver cancer | 82 (0) | 72 [63–76] | ||
| Lung cancer | 448 (0) | 70 [62–77] | ||
| Oesophageal cancer | 104 (0) | 71 [61–79] | ||
| Pancreatic cancer | 110 (0) | 73 [65–80] | ||
| Prostate cancer | 643 (0) | 79 [72–84] | ||
| Stomach cancer | 100 (0) | 75 [65–81] | ||
| Testis cancer | 9 (0) | 52 [44–55] | ||
| Thyroid gland cancer | 6 (0) | 76 [47–78] | ||
| Other or no cancera | 104,888 (2.9) | 50 [39–66] | ||
| Other cause | Bladder cancer | 53,867 (1.5) | 77 [69–84] | |
| CNS cancer | 24,204 (0.7) | 64 [53–73] | ||
| Colorectal cancer | 130,632 (3.5) | 76 [67–82] | ||
| Cutaneous melanoma | 12,298 (0.3) | 68 [56–78] | ||
| Head and neck cancer | 46,689 (1.3) | 62 [54–71] | ||
| Kidney cancer | 30,515 (0.8) | 73 [63–81] | ||
| Larynx cancer | 19,431 (0.5) | 66 [57–76] | ||
| Liver cancer | 80,578 (2.2) | 71 [63–78] | ||
| Lung cancer | 309,349 (8.4) | 68 [59–77] | ||
| Oesophageal cancer | 45,215 (1.2) | 68 [58–77] | ||
| Pancreatic cancer | 61,217 (1.7) | 71 [62–79] | ||
| Prostate cancer | 154,378 (4.2) | 82 [75–87] | ||
| Stomach cancer | 43,501 (1.2) | 74 [64–81] | ||
| Testis cancer | 1503 (0) | 45 [33–63] | ||
| Thyroid gland cancer | 2227 (0.1) | 72 [62–80] | ||
| Other or no cancera | 2,562,179 (70) | 78 [67–86] | ||
| Women | Overall | 3,553,707 (100) | 84 [76–90] | |
| Suicide | Bladder cancer | 10 (0) | 76 [57–87] | |
| Breast cancer | 264 (0) | 63 [52–74] | ||
| CNS cancer | 4 (0) | 62 [50–77] | ||
| Colorectal cancer | 53 (0) | 73 [63–83] | ||
| Corpus uteri cancer | 7 (0) | 70 [62–77] | ||
| Cutaneous melanoma | 6 (0) | 77 [74–79] | ||
| Head and neck cancer | 17 (0) | 61 [57–76] | ||
| Kidney cancer | 11 (0) | 73 [62–81] | ||
| Larynx cancer | 4 (0) | 54 [50–59] | ||
| Liver cancer | 4 (0) | 68 [63–72] | ||
| Lung cancer | 37 (0) | 67 [56–78] | ||
| Oesophageal cancer | 10 (0) | 73 [51–80] | ||
| Ovary cancer | 8 (0) | 66 [58–70] | ||
| Pancreatic cancer | 19 (0) | 71 [68–81] | ||
| Stomach cancer | 9 (0) | 64 [53–70] | ||
| Thyroid gland cancer | 5 (0) | 79 [67–81] | ||
| Other or no cancera | 37,829 (1.1) | 53 [42–68] | ||
| Other cause | Bladder cancer | 16,694 (0.5) | 82 [75–88] | |
| Breast cancer | 180,821 (5.1) | 74 [60–84] | ||
| CNS cancer | 18,831 (0.5) | 68 [57–77] | ||
| Colorectal cancer | 116,793 (3.3) | 80 [71–87] | ||
| Corpus uteri cancer | 10,105 (0.3) | 75 [67–82] | ||
| Cutaneous melanoma | 10,472 (0.3) | 73 [57–83] | ||
| Head and neck cancer | 9,737 (0.3) | 67 [56–80] | ||
| Kidney cancer | 17,161 (0.5) | 78 [69–85] | ||
| Larynx cancer | 2,125 (0.1) | 67 [57–79] | ||
| Liver cancer | 28,184 (0.8) | 77 [69–84] | ||
| Lung cancer | 89,479 (2.5) | 69 [57–79] | ||
| Oesophageal cancer | 10,597 (0.3) | 75 [63–83] | ||
| Ovary cancer | 47,964 (1.4) | 73 [63–81] | ||
| Pancreatic cancer | 57,766 (1.6) | 78 [69–84] | ||
| Stomach cancer | 25,717 (0.7) | 80 [70–87] | ||
| Thyroid gland cancer | 3,896 (0.1) | 79 [71–86] | ||
| Other or no cancera | 2,869,068 (81) | 86 [79–91] | ||
CNS Central nervous system, IQR Interquartile range
aIncludes other cancer sites, multiple cancers, and haematological malignancies